Program Overview
This CME/CNE program is derived from content presented at the Congress of Clinical Rheumatology 2019. The expert faculty will provide clinicians with an overview of the immunopathogenesis of psoriatic arthritis (PsA). The faculty will analyze the most recent data for the treatment of PsA, highlighting the clinical relevance of both current and emerging therapeutic agents. Managing patients with psoriatic arthritis, including adverse events, will be reviewed. The faculty will relay strategies for making informed treatment decisions and providing optimal care that learners may apply to their daily practice.
Target Audience
Rheumatologists, physicians, internists, nurses, nurse practitioners, physician assistants, and other healthcare providers that are involved in the management of psoriatic arthritis
Agenda
- An Update on Psoriatic Arthritis: Early & Accurate Diagnoses
- Clinical Trial Update of Current and Emerging Therapeutics for the Management of PsA
- The Importance of Collaborating with the Healthcare Team to Create Individualized Treatment Strategies to Minimize Joint Damage and Long-Term Disability
Faculty
Alan L. Epstein, MD
Clinical Professor of Medicine
University of Pennsylvania School of Medicine
Attending Physician, Pennsylvania Hospital
Philadelphia, Pennsylvania
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
| Faculty | Relationship Identified With: |
| Alan L. Epstein, MD | Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech Inc.; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Merck & Co.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Quest Pharmaceuticals, Inc.; Regeneron; Sanofi-aventis U.S. LLC |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hours). Provider number P0491.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by independent educational grants from Celgene Corporation, Novartis Pharmaceuticals Corporation and UCB, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Celgene Corporation, Novartis Pharmaceuticals Corporation and UCB, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
